GW Pharmaceuticals Provides Preliminary Fourth Quarter and Full-Year 2020 Net Product Sales Results and 2021 Program Milestones

 Total preliminary net product sales of approximately $148 million for the fourth quarter and approximately $526 million for the full

Read more

GW Pharmaceuticals plc Reports Third Quarter 2020 Financial Results and Operational Progress

– Total revenue increased 51 percent to $137.1 million – – Epidiolex for seizures associated with TSC launched in the U.S. –– Nabiximols Phase 3 program in MS spasticity now recruiting –– Conference call today

Read more

Perrigo Partners With Kazmira LLC To Enter CBD Market Through A Two-Phased, Science-Based Approach

DUBLIN, June 17, 2020 /PRNewswire/ — Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of Quality, Affordable Self-Care Products, announced today

Read more